Atrasentan, an Endothelin-Receptor Antagonist for Refractory Adenocarcinomas: Safety and Pharmacokinetics
- 15 April 2002
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 20 (8) , 2171-2180
- https://doi.org/10.1200/jco.2002.08.028
Abstract
PURPOSE: Endothelin receptors, particularly the ETA receptor, have been shown to participate in the pathophysiology of prostate and other cancers. Atrasentan, an endothelin antagonist, binds select...Keywords
This publication has 29 references indexed in Scilit:
- The Roles of Endothelins in Proliferation, Apoptosis, and AngiogenesisPublished by Springer Nature ,2001
- Endothelins as Autocrine Regulators of Tumor Cell GrowthTrends in Endocrinology & Metabolism, 1998
- Behavioral signs of acute pain produced by application of endothelin-1 to rat sciatic nerveNeuroReport, 1998
- Vasoactive Peptides Modulate Vascular Endothelial Cell Growth Factor Production and Endothelial Cell Proliferation and InvasionPublished by Elsevier ,1997
- Endothelin induces vasoconstriction in the bone vasculature in vitro: An effect mediated by a single receptor populationJournal of Orthopaedic Research, 1996
- The endothelin system and its potential as a therapeutic target in cardiovascular diseasePharmacology & Therapeutics, 1996
- Contribution of endogenous generation of endothelin-1 to basal vascular toneThe Lancet, 1994
- Growth regulatory properties of endothelinsPeptides, 1993
- Sexual dimorphism of blood pressure in spontaneously hypertensive rats is androgen dependentLife Sciences, 1991
- A novel potent vasoconstrictor peptide produced by vascular endothelial cellsNature, 1988